Controlling Ring Translation of Rotaxanes

Antje Vetter and Werner Abraham*

Humboldt-Universität zu Berlin, Institute of Chemistry, Brook-Taylor-Str. 2, D-12489 Berlin, Germany

Full synthetic details pertaining to the preparations of new compounds.

UV-vis and NMR spectra of selected compounds and transients; Assignment of protons of rotaxanes 3, 4, 6, 10, 12, 14, 16, 19 and 21 and the molecular axles 22 - 24

Transient decay curves of compound 12, 25, 21,22 and 26; absorption spectrum and decay curve of the transient observed upon irradiation of $CBQT^{4+}$ in MeOH.

A solution of $1^{[1]}$ (0.404 g, 0.57 mmol) in acetone (30 mL) were cooled to 0 °C.CrO₃ (0.315 g, 3.15 mmol) dissolved in H₂SO₄ (3 moll⁻¹) were slowly dropped into the acetone solution whereby the temperature was hold below 5 °C. The suspension was stirred for 3 h at 0 °C. Water (30 mL) and dichloromethane (DCM) (40 mL) were added. The organic phase was seoarated and the aqueous phase was extracted with DCM (2 x 40 mL). The combined organic phases were were dried (MgSO₄), the solvent was removed in vacuo. The residue was chromatographed (silica gel, acetonitrile (200 mL)/0.5% NH₄PF₆ aqueous solution (5 mL)). The solvent was separated. The aqueous solution was extracted with DCM (3 x 30 mL). The organic layer was separated. The aqueous solution was extracted with DCM (3 x 30 mL). The combined organic solutions were dried (MgSO₄). The solvent was evaporated to give pure **2** as orange resin, 0.320 g, (79 %).

¹H-NMR (400 MHz, CD₃CN, TMS): $\delta = 2.50$ (t, *J*=8 Hz, 2 H; CH₂), 2.77 (t, *J*=8 Hz, 2 H; CH₂), 3.67-3.69 (m, 4 H; ethyleneoxy), 3.79 (t, *J*=5 Hz, 2 H; ethyleneoxy), 3.89 (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.07 (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.28 (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.79 (s, 3 H; N⁺Me), 6.83 (d, *J*=9 Hz, 2 H; aryl), 7.09 (d, *J*=9 Hz, 2 H; aryl), 7.27 (d, *J*=9 Hz, 2 H; aryl), 7.44 (d, *J*=9 Hz, 2 H; aryl), 7.85 (m, 2 H; acridinium); 8.11 (d. *J*=9 Hz, 2 H; acridinium), 8.35 (m, 2 H; acridinium), 8.58 (d, *J*=9 Hz, 2 H; acridinium); HRMS (ESI) found 566,2531, calcd for (M-PF₆)[C₃₅H₃₆O₆N]⁺) 566.2537.



Scheme S1 Synthesis of the western part of the molecular axle 8

10-Methyl-9-(4-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)phenyl)acridinium

hexafluorophosphate: 2-(2-(2-(4-(9-methoxy-10-methyl-4a,9,9a,10-tetrahydroacridin-9yl)phenoxy)ethoxy)ethoxy)ethanol^[11] (0.80 g, 1.73 mmol) dissolved in THF (50 mL) were treated with NaH (0.117 g, 0.29 mmol, 60% in hexane). The mixture was stirred for 30 min. Propargyl bromide (0.28 g, 1.90 mmol) was added and the solution was heated under reflux for 5 hours and stirred at room temperature for 12 hours. NH₄PF₆ (15 mL, 5% in water) was added. The solvent was removed in vacuo. The residue was treated with water (15 mL) and dichloromethane (DCM) (30 mL). The organic phase was separated. The aqueous phase was extracted with DCM (3x 30 mL). The combined organic phases were dried (MgSO₄); the solvent was removed in vacuo. The remaining residue was purified by column chromatography (CC) (SiO₂/acetone (400 mL)/cyclohexane (40 mL)/NH₄PF₆ (0.5 g). The obtained product was isolated; the solvents were evaporated. Water (30 mL) was added to the remaining solid. The aqueous phase was extracted with DCM (3x 30 mL). The combined organic phases were dried (MgSO₄). The solvent was removed in vacuo to give the substituted acridinium salt (0.43 g, 41%) as orange-red resin. ¹H-NMR (400 MHz, CD₃CN, TMS): $\delta = 2.68$ (t, J=2 Hz, 1 H; propargyl), 3.63-3.61 (m, 6 H; ethyleneoxy), 3.69-3.67 (m, 2 H; ethyleneoxy), 3.89 (t, J=5 Hz, 2 H; ethyleneoxy), 4.14 (d, J=2 Hz, 2 H; CH₂), 4.29 (t, J = 5 Hz, 2H; ethyleneoxy), 4.81 (s, 3 H; N⁺Me), 7.27 (d, J=9 Hz, 2 H; aryl), 7.46 (d, J=9 Hz, 2 H; aryl), 7.84 (t, J=8 Hz, 2 H; acridinium); 8.11 (d. J=9 Hz, 2 H; acridinium), 8.37 (t, J=8 Hz, 2 H; acridinium), 8.60 (d, J=9 Hz, 2 H; acridinium); HRMS (ESI) found 456.2167, calcd for (M-PF₆)[C₂₉H₃₀O₄N]⁺) 456.2169.

9-Methoxy-10-methyl-9-(4-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)phenyl)-9,10dihydroacridine (8)

Thesuspensionof10-Methyl-9-(4-(2-(2-(2-(prop-2-
ynyloxy)ethoxy)ethoxy)ethoxy)phenyl)acridinium hexafluorophosphate(0.18 g, 0.30 mmol)dissolved in MeCN (5 mL) and MeOH (0.5 mL) and K2CO3 (0.1 g) was stirred for 12 h. After
filtration the solvent was removed in vacuo. The residue was extracted with chloroform (5 mL).
The solid was filtered and the solvent was removed in vacuo to give 8 (0.145 g, 99%), brown oil.

¹H-NMR (400 MHz, CDCl₃, TMS): δ = 2.39 (t, *J*=2 Hz, 1 H; propargyl), 2.95 (s, 3 H; OMe), 3.50 (s, 3 H; NMe), 3.71-3.63 (m, 8 H; ethyleneoxy), 3.79 (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.05 (t, *J*=5 Hz; 2H; ethyleneoxy), 4.16 (d, *J* = 2 Hz, 2 H; OCH₂), 6.76 (d, *J*=9 Hz, 2 H; aryl); 6.92 (t, *J*=8 Hz, 2 H; acridane H-5,7), 7.02 (d, *J*=8 Hz, 2 H; acridane H-4,5), 7.21 (d, *J*=9 Hz, 2 H; aryl), 7.28 (t, *J*=8 Hz, 4 H; acridane H-3,6); HRMS (ESI) found 456.2167 calcd for (M-MeO⁻), [C₂₉H₃₀O₄N]⁺ 456.2169.



Scheme S2 Synthesis of the eastern part of the molecular axle 9

10-Methyl-9-(4-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)phenyl)acridinium hexafluorophosphate

 $2-(2-(2-(4-bromophenoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate^[1] (3.1 g, 6.8 mmol) was dissolved in dry THF (30 mL) under an argon atmosphere. The solution was cooled to <math>-78^{\circ}$ C and BuLi (1.6 M in n-hexane, 4.2 mL, 6.8 mmol) was dropped into the solution within 30 min. A solution of N-methylacridinone (0.80 g, 3.8 mmol) in THF solution (50 mL) was dropped in this

solution at -78°C. The reaction mixture was stirred for 30 min. at -78°C and then for 20 h at room temperature. Water (2 mL) was added to the violet solution. After filtration and removing of the solvent in vacuum the remaining oil was purified by column chromatography (n-butanol/acetic acid/water 5:1:2) to separate the product from N-methylacridinone. The product (as acetate) was treated with an aqueous saturated solution of NH_4PF_6 (50 mL), dissolved in dichloromethane and purified by column chromatography (MeCN/NH₄PF₆ in MeCN solution (5 %), 40:1), yellow solid, m.p.140 °C, 1.6 g (33 %). ¹H-NMR (400 MHz, CD₃CN, TMS): δ = 2.40 (s, 3 H; CH₃), 3.5 (m, 2 H; ethyleneoxy), 3.6 (m, 4 H; ethyleneoxy), 3.8 (m, 2 H; ethyleneoxy), 4.1 (m, 2 H; ethyleneoxy), 4.3 (m, 2 H; ethyleneoxy), 7.27 (d, *J*(H,H)=8.7 Hz, 2 H; Ar), 7.41 (d, *J*(H,H)=8.1 Hz, 2 H; Ar), 7.45 (d, *J*(H,H)=8.8 Hz, 2 H; Ar), 7.76 (d, *J*(H,H)=8.2 Hz, 2 H; Ar), 7,83 (m, 2 H; acridinium, H-2,7), 8.16 (d, *J*(H,H)=7.5 Hz, 2 H; acridinium, H-1,8), 8.35 (m, 2 H; acridinium, H-3,6), 8.57 (d, *J*(H,H)=9.3 Hz, 2 H; acridinium, H-4,5). C₃₃H₃₄F₆NO₆PS (717.66): calcd. (%): C 55.23, H 4.77, N 1.45, S 4.47; found (%): C 55.17, H 5.08, N 1.60, S 4.37.

9-(4-(2-(2-(2-azidoethoxy)ethoxy)phenyl)-10-methylacridinium hexafluorophosphate (9)

10-Methyl-9-(4-(2-(2-(tosyloxy)ethoxy)ethoxy)phenyl)acridinium hexafluorophosphate (0.8 g, 1.11 mmol) dissolved in dry DMF (20 mL) and NaN₃ (0.8 g (12.3 mmol) were stirred for 14 hours at 60 °C. After cooling water (40 mL) and ethyl acetate (40 mL) were added. The organic phase was separated. The water phase was extracted with ethyl acetate (4x 50 mL). The combined organic phases were dried (MgSO₄). The solvent was removed in vacuo. The residue was purified by CC (SiO₂/ acetone (400 mL)/cyclohexane (40 mL)/NH₄PF₆ (0.5 g)). The yellow product fraction was evaporated. The residue was treated with water (30 mL) and DCM (30 mL). The aqueous phase was extracted with DCM (2x 30 mL). The combined organic phases were dried (MgSO₄) and evaporated to give **9** as orange resin (0.43 g, 65%).

¹H-NMR (400 MHz, CD₃CN, TMS): $\delta = 3.39$ (t, *J*=5 Hz, 2 H; CH₂N₃), 3.64 (m, 4 H; ethyleneoxy), 3.71 (t, *J*=5 Hz, 2 H; CH₂O), 3.90 (t, *J*=5 Hz, 2 H; CH₂O), 4.30 (t, *J*=5 Hz, 2 H; OCH₂), 4.80 (s, 3 H; N⁺Me), 7.29 (d, *J*=9 Hz, 2 H; aryl), 7.47 (d, *J*=9 Hz, 2 H; aryl), 7.86 (m, 2 H; acridinium, H-2,7), 8.13 (d, *J*=9 Hz, 2 H; acridinium, H-1,8), 8.37 (m, 2 H; acridinium, H-3,6), 8.59 (d, *J*=9 Hz, 2 H; acridane, H-4,5); HRMS: found 443.2075, calcd for (M-PF₆⁻), [C₂₆H₂₇O₃N₄]⁺ 443.2078; IR: 2160 cm⁻¹.

Compound 13

4-(3-(2-(2-(2-(4-(9-ethoxy-10-methyl-9,10-dihydroacridin-9-

yl)phenoxy)ethoxy)ethoxy)propyl)phenol^[1] (0.400 g, 0.69 mmol) and propargylbromide (0.163 g, 163 mmol) were dissolved in MeCN (30 mL). K₂CO₃ (0.190 g, 1.37 mmol) was added.

The suspension was refluxed for 8 h and stirred for 12 h at room temperature. The solvent was evaporated. The residue was treated 5% aqueous NH₄PF₆ solution and DCM (30 mL). The aqueous solution was extracted with DCM (2 x 30 mL). The combined organic phases were dried (MgSO₄) and evaporated. The crude product was purified by CC (silica gel, acetone (400 mL)/cyclohexane (40 mL)/NH₄PF₆ (0.5 g)). The yellow fractions were evaporated and NH₄PF₆ was dissolved with water (30 mL). The aqueous suspension was extracted with DCM (3 x 30 mL). The DCM solutions were dried and evaporated to give the acridinium salt as an orange resin, 0.287 g (57 %). ¹H-NMR (400 MHz, CD₃CN, TMS) (¹³C 100 MHz): $\delta = 1.81-1.73 (31.0) \text{ (m, 2 H;}$ CH₂), 2.59 (31.4) (t, J=7 Hz, 2 H; CH₂), 2.74 (t, J=2 Hz, 1 H: propargyl), 3.42 (75.6) (t, J=7 Hz, 2 H; CH₂O), 3.51-3.53 (m, 2 H; ethyleneoxy), 3.56-3.58 (m, 2 H; ethyleneoxy), 3.61-3.63 (m, 2 H; ethyleneoxy), 3.67-3.69 (m, 2 H; ethyleneoxy), 3.88 (69.2) (t, J=5 Hz, 2 H; ethyleneoxy), 4.28 (68.0) (t, J=5 Hz, 2 H; ethyleneoxy), 4.62 (55.5) (d, J=2 Hz, 2 H, propargyl,CH₂), 4.79 (38.7) (s, 3 H; N⁺Me), 6.82 (114.6) (d, J=9 Hz, 2 H; aryl); 7.11 (129.4) (d, J=9 Hz, 2 H; aryl), 7.27 (114.9) (d, J=9 Hz, 2 H; aryl), 7.44 (130.5) (d, J=9 Hz, 2 H; aryl), 7.84 (127.6) (m, 2 H; acridinium, H-3,6), 8.11 (132.0) (m, 2 H; acridinium, H-4,5), 8.37 (138.6) (m, 2 H; acridinium, H-2,7), 8.58 (118.4) (m, 4 H; acridinium, H-1,8), HRMS (ESI) found 590.2900, calcd for (M-PF₆)[C₃₈H₄₀O₅N]⁺ 590.2901

The resin was transformed into the acridane compound **13**. K_2CO_3 (0.1 g) was added to 0.250 g (0.34 mmol) resin dissolved in MeCN (5 mL) and MeOH (0.5 mL). The suspension was stirred for 12 h. After filtration the solvent was removed in vacuo. The residue was extracted with chloroform (5 mL). The solid was filtered and the solvent was removed in vacuo to give **13**, 0.200 g (95 %).

¹H-NMR (400 MHz, CDCl₃, TMS) (¹³C 100 MHz): δ = 1.81-1.85 (31.3) (m, 2 H; CH₂), 2.49 (75.3) (t, *J*=2 Hz, 1 H; propargyl), 2.61 (31.3) (t, *J*=7 Hz, 2 H; CH₂), 2.94 (55.8) (s, 3 H; OCH₃), 3.43 (t, *J*=7 Hz, 2 H; CH₂O), 3.49 (33.4) (s, 3 H; N⁺Me), 3.60-3.73 (m, 8 H; ethyleneoxy), 3.79 (69.7) (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.05 (67.2) (t, *J*=5 Hz, 2 H; ethyleneoxy), 4.63 (d, *J*=2 Hz, 2 H; propargyl), 6.75 (113.7) (d, *J*=9 Hz, 2 H; aryl); 6.85-6.89 (114.7, 120.1) (m, 4 H; aryl, acridane-H3,6), 7.02 (112.1) (d, *J*=9 Hz, 2 H; acridane-H1,8), 7.09 (129.3) (d, *J*=9 Hz, 2 H; aryl), 7.21 (127.4) (d, *J*=9 Hz, 2 H; aryl), 7.29 (128.3, 129.3) (m, 4 H; acridane-H-2,4,5,7), HRMS (ESI) found 644.2994, calcd for (M+Na²³)[C₃₉H₄₃O₆N²³Na] 644.2983, found 590.2900, calcd for (M-MeO⁻)[C₃₈H₄₀O₅N]⁺ 590.2901.



Scheme S3 Synthesis of the molecular axle 17

N-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethyl)aniline

K₂CO₃ (4.7 g, 34.01 mmol) was added to the solution of 2-(2-(2-(prop-2ynyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate^[2] (3.63 g , 10.6 mmol) and aniline (3.22 g, 34.58 mmol) in MeCN (40 mL). The suspension was refluxed for 20 h. The solvent was evaporated in vacuo. The remaining residue was treated with water (30 mL) and diethylether (30 mL). The organic layer was separated. The aqueous phase was extracted with diethylether (3 x 30 mL). The combined organic phases were dried (MgSO₄). After removing the solvent the residue was purified by CC (silica gel, cyclohexane/ethylacetate 2:1) to give 2.1 g (75 %) oil. ¹H-NMR (400 MHz, CDCl₃, TMS): δ = 3.29 (t, *J*=5 Hz, 2 H; NCH₂), 3.64-3.67 (m, 10 H; ethyleneoxy), 4.19 (d, *J*=2 Hz, 2 H; propargyl), 4.41 (t, *J*=5 Hz, 1 H; propargyl), 6.63 (d, *J*=8 Hz, 2 H; Ar), 6.71 (t, *J*=8 Hz, 1 H; Ar), 7.17, (t, *J*=8 Hz, 2 H; Ar).

10-methyl-9-(4-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethylamino)phenyl)acridinium hexafluorophosphate

N-(2-(2-(2-(prop-2-vnvloxy)ethoxy)ethoxy)ethyl)aniline (1.00)3.8 mmol) and Ng, methylacridinium iodide (1.22 g, 3.8 mmol) in n-butanol (40 mL) were refluxed for 8 h.while air bubbled through the suspension.. The solvent was evaporated in vacuo. The residue was purified by CC (silica gel, acetone (400 mL)/cyclohexane 40 mL)/0.5 g NH₄PF₆). The violet fractions were collected. The solvents were evaporated in vacuo. The residue was treated with water (30 mL). The suspension was extracted with DCM (3 x 30 mL). The DCM-solution was dried (MgSO₄) and evaporated to give a violet resin, 1.09 g (48 %). ¹H-NMR (400 MHz, CD₃CN, TMS): $\delta = 2.68$ (t, J=2 Hz, 1 H; propargyl), 3.41 (t, J=5 Hz, 2 H; NCH₂), 3.61-3.63 (m, 8 H; ethyleneoxy), 3.73 (t, J=5 Hz, 2 H; OCH₂), 4.15 (d, J=2 Hz, 2 H; propargyl), 4.72 (s, 3 H; N⁺Me), 6.94 (d, J=9 Hz, 2 H; aryl), 7.33 (d, J=9 Hz, 2 H; aryl), 7.82 (m, 2 H; acridinium, H-2,7); 8.26 (d. J=8 Hz, 2 H; acridinium, H-1,8), 8.37 (m, 2 H; acridinium, H-3,6), 8.51 (d, J=9 Hz, 2 H; acridinium, H-4,5).

4-(9-methoxy-10-methyl-9,10-dihydroacridin-9-yl)-N-(2-(2-(2-(prop-2-

ynyloxy)ethoxy)ethoxy)ethyl)aniline (17)

The suspension of 10-methyl-9-(4-(2-(2-(prop-2-

ynyloxy)ethoxy)ethoxy)ethylamino)phenyl)acridinium hexafluorophosphate (0.50 g, 0.83 mmol) dissolved in MeCN (5 mL) and MeOH (0.5 mL) and K₂CO₃ (0.1 g) was stirred for 12 h. After filtration the solvent was removed in vacuo. The residue was extracted with chloroform (5 mL). The solid was filtered and the solvent was removed in vacuo to give **17** (0.402 g, 100%), red oil. ¹H-NMR (400 MHz, CDCl₃, TMS): δ = 2.39 (t, *J*=2 Hz, 1 H; propargyl), 2.95 (s, 3 H; OMe), 3.23 (t, *J*=6 Hz, 2 H; NCH2), 3.48 (s, 3 H; NMe), 3.61-3.73 (m, 10 H; ethyleneoxy), 4.17 (d, *J* = 2 Hz, 2 H; propargyl), 6.76 (d, *J*=9 Hz, 2 H; aryl); 6.48 (d, *J*=9 Hz, 2 H; aryl), 6.92 (m, 2 H; acridane H-2,7), 7.01 (d, *J*=9 Hz, 2 H; acridane, H-4,5), 7.09 (d, *J*=9 Hz, 2 H; Ar), 7.27 (m, 4 H; acridane H-3,6), 7.33 (d, *J*=9 Hz, 2 H; acridane, H-1,8).



Scheme S4 Synthesis of the molecular thread 18

2-(2-(methyl(phenyl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate

Toluene sulfochloride (5.83 g, 30.58 mmol) dissolved in DCM (20 mL) were added to 2-(2-(2-(methyl(phenyl)amino)ethoxy)ethoxy)ethanol^[4] (1.34 g, 5.58 mmol) in DCM (10 mL). NaOH (5.81 g, 145.26 mmol) and DCM (30 mL) were added. The blue solution was refluxed for 7 h. The formed suspension was given to water (150 mL) and DCM (50 mL). The organic layer was separated. The aqueous phase was extracted with DCM (3 x 50 mL). The combined organic phases were dried (MgSO₄) and evaporated. Purification by CC (silica gel, cyclohexane/ethylacetate 2:1) affords a yellowish oil, 2.00 g (91 %). ¹H-NMR (400 MHz, CD₃CN, TMS): δ = 2.42 (s, 3 H; methyl), 2.94 (s, 3 H; NCH₃), 3.48-3.55 (m, 6 H; ethyleneoxy), 3.59 (s br, 2 H; OCH₂), 3.65 (t, *J*=5 Hz, 2 H; NCH₂), 4.12 (t, *J*=5 Hz, 2 H; OCH₂), 6.68 (s br, 3 H; aryl), 7.20 (s br, 2 H; aryl), 7.32 (d, *J*=8 Hz, 2 H; Ar), 7.78 (d, *J*=8 Hz, 2 H; Ar).

9-(4-((2-(2-(2-iodoethoxy)ethoxy)ethyl)(methyl)amino)phenyl)-10-methylacridinium hexafluorophosphate

2-(2-(2-(methyl(phenyl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (1.06 g, 2.69 mmol) and N-methylacridinium iodide (0.86 g, 2.69 mmol) were heated in boiling n-butanol (40 mL) for 7 h while air bubbled through the suspension. The solvent was evaporated in vacuo. The residue was purified by CC (silica gel, acetone (400 mL)/cyclohexane (40 mL)/NH₄PF₆ (0.5 g). The violet fractions were treated with water (30 mL). The mixture was extracted with DCM (3 x 30 mL). The combined DCM-solutions were dried (MgSO₄) and evaporated in vacuo to give a violet resin, 1.38 g (75 %). ¹H-NMR (400 MHz, CD₃CN, TMS): δ = 3.13 (s, 3 H; NMe), 3.26 (t, *J*=6 Hz, 2 H; CH₂I), 3.60 (s, 4 H; ethyleneoxy), 3.70 (t, *J*=6 Hz, 4 H; NCH₂, OCH₂), 3.74 (m, 2 H; OCH₂), 4.71 (s, 3 H; N⁺Me), 7.05 (d, *J*=9 Hz, 2 H; aryl), 7.40 (d, *J*=9 Hz, 2 H; aryl), 7.82 (m, 2 H; acridinium, H-2,7); 8.26 (d, *J*=8 Hz, 2 H; acridinium, H-1,8), 8.31 (m, 2 H; acridinium, H-3,6), 8.50 (d, *J*=9 Hz, 2 H; acridinium, H-4,5).

9-(4-((2-(2-(2-azidoethoxy)ethoxy)ethyl)(methyl)amino)phenyl)-10-methylacridinium hexafluorophosphate (18)

9-(4-((2-(2-(2-iodoethoxy)ethoxy)ethyl)(methyl)amino)phenyl)-10-methylacridinium

hexafluorophosphate (1.24 g, 1.81 mmol) and NaN₃ (1.3 g (19.91 mmol) dissolved in dry DMF (30 mL) were stirred for 16 h at 80 °C. The suspension was treated with water (40 mL) and DCM (40 mL). The organic layer was separated. The aqueous solution was extracted with DCM (2 x 30 mL). The combined DCM-solutions were dried (MgSO₄) and evaporated. The remaining violet resin was dried in vacuo to give 1.08 g (98 %). ¹H-NMR (400 MHz, CD₃CN, TMS): δ = 3.13 (s, 3 H; NMe), 3.39 (t, *J*=5 Hz, 2 H; OCH₂), 3.64 (m, 4 H; OCH₂), 3.71 (t, *J*=5 Hz, 2 H; ethyleneoxy), 3.90 (t, *J*=5 Hz, 2 H; NCH₂), 4.30 (t, *J*=5 Hz, 2 H; CH₂N₃), 4.71 (s, 3 H; N⁺Me), 7.05 (d, *J*=9 Hz, 2 H; aryl), 7.40 (d, *J*=9 Hz, 2 H; aryl), 7.82 (m, 2 H; acridinium, H-2,7), 8.26 (d. *J*=9 Hz, 2 H; acridinium, H-1,8), 8.31 (m, 2 H; acridinium, H-3,6), 8.50 (d, *J*=9 Hz, 2 H; acridinium, H-4,5). HRMS: found 456.2395, calcd for (M-PF₆⁻), [C₂₇H₃₀O₂N₅]⁺ 456.2394.

Molecular axle 22

The axle **11** (0.16 g, 0.13 mmol) dissolved in MeCN/MeOH (5mL/0.5 mL) was stirred with $K_2CO_3(0.1g)$ for 12 hours. The precipitate was filtered off. The solvent was removed in vacuo. The residue was extracted with dry chloroform (3x 5mL). The solution was evaporated to afford **21** (0.12 g, 93 %) which was used without further purification.

¹H NMR (400 MHz, CD₃CN, TMS) (¹³C 100 MHz): $\delta = 2.9$ (50.6) (s, 6 H; OMe), 3.42 (33.1) (s, 6 H; NMe), 3.5 (70.1, 70.3) (m, 12 H; ethyleneoxy), 3.6 (69.3) (m, 4 H; ethyleneoxy), 3.72 (69.0) (t, *J*(H,H)=5.0 Hz, 2 H; ethyleneoxy), 3.9 (67.3) (m, 4 H; ethyleneoxy), 4.37 (49.6) (t, *J*(H,H)=5.0 Hz, 2 H; NCH₂), 4.43 (63.9) (s, 2 H; OCH₂), 6.70 (112.8) (dd, *J*(H,H)=9.0, 8.8 Hz, 4 H; Ar), 6.88

(120.1) (m, 4 H; acridane, H-2,7), 7.07 (113.6) (d, J(H,H)=7.5 Hz, 4 H; acridane, H-4,5), 7.13 (d, J(H,H)=8.6 Hz, 4 H; Ar), 7.2 (128.6) (m, 8 H; acridane, H-1,3,6,8), 7.72 (124.0) (s, 1 H; triazole); HRMS (ESI): found 930.4436; calcd for [M-MeO⁻] [C₅₆H₆₀O₈N₅]⁺: 930.4425; found 449.7130; calcd for. [M-2 MeO⁻] [C₅₆H₆₀O₈N₅]²⁺: 449.7124.

Molecular axle 23

The axle **15** (0.158 g, 0.10 mmol) dissolved in MeCN/MeOH (5mL/0.5 mL) was stirred with $K_2CO_3(0.1g)$ for 12 hours. The precipitate was filtered off. The solvent was removed in vacuo. The residue was extracted with dry chloroform (3x 5mL). The solution was evaporated to afford **23** (0.011 g, 87 %) which was used without further purification.

¹H NMR (400 MHz, CD₃CN, TMS) (¹³C 100 MHz): $\delta = 1.72$ (31.2) (m, 2 H; CH₂), 2.52 (30.8) (t, *J*(H,H)=8 Hz, 2.9 (50.3) (s, 6 H; OMe), 3.34 (70.1) (t, *J*(H,H)=6 Hz, 2 H; OCH₂), 3.42 (32.8) (s, 6 H; NMe), 3.4-3.5 (69.1-70.0) (m, 12 H; ethyleneoxy), 3.6 (69.3) (m, 4 H; ethyleneoxy), 3.72 (69.0) (t, *J*(H,H)=5.0 Hz, 2 H; OCH₂), 3.9 (67.1) (m, 4 H; ethyleneoxy), 4.42 (49.8) (t, *J*(H,H)=5.0 Hz, 2 H; NCH₂), 4.96 (61.1) (s, 2 H; OCH₂), 6.66 (113.3), 6.69 (113.6) (dd, *J*(H,H)=9.0, 8.8 Hz, 4 H; Ar), 6.88 (119.8) (m, 4 H; acridane, H-2,7), 7.07 (126.7) (d, *J*(H,H)=9 Hz, 4 H; Ar), 7.1 (112.5, 126.7) (m, 8 H; Ar, acridane, H-4,5), 7.3 (128.3) (m, 8 H; acridane, H-1,3,6,8), 7.84 (124.0) (s, 1 H; triazole); HRMS (ESI): found 1067.5362; calcd for [M-MeO⁻] [C₆₅H₆₉D₂O₉N₅]⁺: 1067.5372; found 516.7495; calcd for. [M-2 MeO⁻] [C₆₅H₆₉D₂O₉N₅]²⁺: 516.7489.

Molecular axle 24

The axle **20** (0.15 g, 0.13 mmol) dissolved in MeCN/MeOH (5 mL/0.5 mL) was stirred with $K_2CO_3(0.1 \text{ g})$ for 12 h. The precipitate was filtered off. The solvent was removed in vacuo. The residue was extracted with dry chloroform (3x 5mL). The solution was evaporated to afford **23** (0.04 g, 38 %) as red-brown oil that was used without further purification.

¹H NMR (400 MHz, CD₃CN, TMS) (¹³C 100 MHz): $\delta = 2.8$ (38.4) (s, 3 H; NMe), 3.89 (50.8) (s, 3 H; OMe), 3.91 (50.7) (s, 3 H; OMe), 3.1 (43.3) (m, 2 H; NHC<u>H</u>₂), 3.3 (52.0) (m, 2 H; MeN<u>CH</u>₂), 3.43-3.5 (33.3, 69.2,69.4,69.6,70.2,70.3,70.3) (m, 22 H; ethyleneoxy, NMe), 3.67 (68.4) (t, *J*(H,H)=4.7 Hz, 2 H; OCH₂), 4.29 (50.0) (t, *J*(H,H)=5.0 Hz, 2 H; NCH₂), 4.47 (64.1) (s, 2 H; OCH₂), 6.40 (111.9) (d, *J*(H,H)=8.8 Hz, 2 H; Ar), 6.51 (111.4) (d, *J*(H,H)=9.0 Hz, 2 H; Ar), 6.87 (117.6) (m, 4 H; acridane, H-2,7), 6.94 (126.7) (d, *J*(H,H)=8.8 Hz, 2 H; Ar), 6.99 (126.7) (d, *J*(H,H)=9.0 Hz, 2 H; Ar), 7.07 (112.8) (d, *J*(H,H)=8.3 Hz, 4 H; acridane, H-4,5), 7.3 (128.7, 128.9) (m, 8 H; acridane, H-1,3,6,8), 7.65 (124.1) (s, 1 H; triazole); HRMS (ESI):

found 942.4910 calcd for [M-MeO⁻] $[C_{57}H_{64}O_6N_7]^+$]: 942.4913; found 455.7365 calcd for [M-2 MeO⁻] $[C_{56}H_{61}O_5N_7]^{2+}$: 455.7362.



Scheme S5 Chemical shift differences of proton resonances of rotaxane **3** obtained by comparison of the proton resonances of compound **5** with related proton resonances observed in the rotaxane ($\delta_4 - \delta_{rotaxane 3}$). Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Scheme S6 Assignable proton signals together with ¹³C signals (in brackets) of rotaxane **6** in acetone- d_6 solution at 233 K. Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra. The red arrow marks the exchange cross peak between protons of two aryl groups of the acridane moieties



Scheme S7 Chemical shift differences of proton resonances of rotaxane **4** obtained by comparison of the proton resonances of compound **4** with related proton resonances observed in the rotaxane ($\delta_5 - \delta_{rotaxane 4}$). Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Scheme S8 Assignable proton signals together with 13 C signals (in brackets) of rotaxane 7 in CD₃CN solution at 298 K.



Figure S1¹H NMR spectrum of rotaxane **10** (CD₃CN) at 298 K



Scheme S9 Chemical shift differences of proton resonances of rotaxane 10 obtained by comparison of the proton resonances of compound 11 with related proton resonances observed in the rotaxane (δ_{11} - $\delta_{rotaxane 10}$).



Figure S2 ¹H NMR spectrum of rotaxane **12** containing 20 % **10** (CD₃OD/CD₃CN 3:1) at 298 K







Scheme S10 Assignment of proton and $({}^{13}C)$ resonances for a) the rotaxane **12** and b) the axle **22** based on two-dimensional NMR-spectroscopy. Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Figure S4 Partial ROESY spectrum of rotaxane **12** at 233 K: red – NOE; blue - exchange cross peaks.



Scheme S11 Assignment of proton and (^{13}C) resonances for the rotaxane **12** in MeOD/CD₃CN (2:1) solution at 233 K. Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra. Red arrows mark exchange peaks observed in the ROESY spectrum at 233 K.



Scheme S12 Chemical shift differences of proton resonances of rotaxane 14 obtained by comparison of the proton resonances of compound 13 with related proton resonances observed in the rotaxane (δ_{13} - $\delta_{rotaxane 14}$). Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Scheme S13 Assignment of proton and (^{13}C) resonances for rotaxane **16** at 233 K MeOD/CD₃CN 1:1) and the axle **23** (298 K in CD₃CN) based on two-dimensional NMR-spectroscopy. Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.





Scheme S14 Chemical shift differences of proton resonances of rotaxane **19** obtained by comparison of the proton resonances of compound **20** with related proton resonances observed in the rotaxane (δ_{20} - $\delta_{rotaxane 19}$). Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Figure S6 ¹H NMR spectrum of rotaxane **21** containing 20 % **19** (CD₃OD/CD₃CN 3:1) at 298 K



Scheme S15 Assignment of proton and (^{13}C) resonances for a) the rotaxane **21** and b) the axle **24** based on two-dimensional NMR-spectroscopy. Blue arrows mark NOE's between protons observed as correlation peaks of ROESY spectra.



Scheme S16 Equilibrium between acridinium and acridane moieties of rotaxane **19** and the axle **24**



Figure S7 UV-Vis-spectra of rotaxanes 10 (red) and 12 (blue) (2.38x10⁻⁵ M in acetonitrile solution)



Figure S8 UV/Vis spectra (MeOH, 3.2×10^{-5} M) of **21**: red; after addition of 1 equiv of HClO₄: black; after addition of 5 x 5 equiv of ethyl-di-*i*-propylamine: blue; after addition of 5 x 1 equiv of HClO₄: green.



Figure S9 Transient UV-Vis-spectra recorded after excitation of the rotaxane **21** (2.60×10^{-5} M in acetonitrile/MeOH 4:1) obtained in situ from the rotaxane **19** by addition of diisopropylethylamine): green – immediately measured; red – 2 min. delay; black – 4 min. delay; blue – 8 min. delay; pink – 15 min. delay.



Figure S10 Transient UV-Vis-spectra recorded after excitation of the molecular axle **24** $(2.1 \times 10^{-5} \text{M in acetonitrile/MeOH 4:1: black – immediately measured; green – 3 min. delay; red – 6 min. delay; black – 12 min delay.$



Figure S11 Transient absorbance at 360 nm recorded after photoexcitation of rotaxane **12** $(5x10^{-5} \text{ M}, \text{ MeOH solution})$ (black) and the one-station rotaxane **25**^[1] $(6x10^{-5}\text{M}, \text{ MeOH solution})$ (red).





Figure S12 Transient absorbance at 360 nm recorded after photoexcitation of rotaxane **21** $(3x10^{-5} \text{ M}, \text{ MeOH solution})$ (blue) and the one-station rotaxane **26**^[1] (5x10⁻⁵M, MeOH solution) (red).





Figure S13 Transient absorbance observed after photoexcitation 313 nm) of the rotaxane **12** $(3.0 \times 10^{-5} \text{M})$ (red) and the molecular axle **22** $(2.92 \times 10^{-5} \text{M})$ (black) in acetonitrile/MeOH 4:1 with identic absorbance at 324 nm.



Figure S14 Transient UV-Vis-spectrum recorded after photoexcitation of **CBQT**⁴⁺ in methanol solution.



Figure S15 Transient UV-Vis spectra of rotaxane **12** (black) and the rotaxane **26**^[3] (red, x 3) recorded after photoexcitation in acetonitrile/methanol 4:1.





Figure S16 Transient UV-Vis spectra of rotaxane **21** (black) and the rotaxane **27**^[1] (blue, x 5) recorded after photoexcitation in acetonitrile/methanol 4:1.



References

- [1] W. Abraham, A. Wlosnewski, K. Buck, S. Jacob, Org. Biomol. Chem. 2009, 7, 142.
- [2] G. Lu, S. Lam, K. Burgess, Chem Commun., 2006, 1652.
- [3] W. Abraham, K. Buck, M. Orda-Zgadzaj, S. Schmidt-Schäffer, U.-W. Grummt, Chem. Commun., 2007, 3094.
- [4] R. Janik, S. Kucharski, A. Kubaiska, B. Lyko, Pol. J. Chem., 2001, 75, 241.